Gastrointestinal (GI) Bleeding

Acute gastrointestinal (GI) bleeding is an important cause of mortality worldwide

Bleeding can occur from the upper or lower GI tract, with upper GI bleeding accounting for most cases


The main causes include peptic ulcer/erosive mucosal disease, oesophageal varices, and malignancy – the case fatality rate is around 10% for upper GI bleeding and 3% for lower GI bleeding, with rebleeding effecting 5-40% of patients and is associated with a four-fold increased risk of death

Research Overview

HALT-IT Trial: TXA for GI bleeding?

The HALT-IT trial assessed whether early administration of tranexamic acid (TXA) in participants with acute GI bleeding can reduce their risk of dying in the hospital.

This trial began recruitment in 2013 and ended in 2019, during this time 12,000 patients were recruited from hospitals worldwide and randomly assigned to receive either TXA or placebo.

The trial investigated the effects of 4 grams of TXA infused over 24-h on death, thromboembolic events and other complications in patients with acute GI bleeding.

GI bleeding is a common emergency with a 10-15% death rate. An effective treatment could save thousands of lives worldwide.

However, the HALT-IT trial results found that TXA does not reduce deaths from gastrointestinal bleeding and showed an increased risk of thromboembolic events (deep vein thrombosis or pulmonary embolism). There were also more seizures with TXA.

On the basis of these results, TXA should not be used for the treatment of GI bleeding outside the context of a randomised trial.

More Resources

Click on watch, read or teach to access videos, publications, and training materials 

More Treatments

TXAcentral is a resource for health professionals caring for people with acute bleeding
TXAcentral brings together randomised trial evidence on the effectiveness and safety of tranexamic acid
Data on many of the trials are also available at the freeBIRD website

In trauma patients with significant bleeding and those with traumatic brain injury (TBI), TXA has been  shown to reduce mortality in both extracranial and intracranial bleeding

Postpartum Haemorrhage (PPH) is the leading cause of maternal death worldwide, responsible for around 100 000 deaths each year. TXA given as quickly as possible after birth and no later than 3 hours, reduces death due to bleeding and the need for surgery to stop bleeding

GI Bleeding is a common emergency that causes substantial mortality and morbidity worldwide. TXA was found to not reduce deaths from GI bleeding and showed an increased risk of thromboembolic events

Every year there are over 300 million surgical procedures worldwide. Bleeding is an important complication and many patients require a blood transfusion. TXA reduces blood loss in surgical patients by about one‐third. However, the effects of TXA on thromboembolic events and mortality in surgery are uncertain

There is ongoing research looking at how Tranexamic Acid (TXA) could be utilised for other bleeding conditions